What the FDA labels say about taking them together
Adalimumab and adalimumab-aaty
Adalimumab-aaty's FDA label of July 8, 2026 names adalimumab in its boxed warning section; the adalimumab labels PlainMeds reads (4) do not name adalimumab-aaty. The adalimumab-aaty label: “Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either Adalimumab-aaty or MTX.”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the adalimumab-aaty FDA label on DailyMed (effective July 8, 2026, CELLTRION USA, Inc.).
What does the adalimumab label say about adalimumab-aaty?
Adalimumab's label (effective October 21, 2025) and its 3 other brand-application labels do not name adalimumab-aaty in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the adalimumab-aaty label say about adalimumab?
Adalimumab-aaty label, boxed warningSERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-aaty, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )].
Adalimumab-aaty label, drug interactionsAlthough MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either Adalimumab-aaty or MTX [see Clinical Pharmacology ( 12.3 )].
Adalimumab-aaty label, warnings and precautionsPatients treated with adalimumab products, including Adalimumab-aaty, are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.
Source: FDA drug label (Adalimumab), CELLTRION USA, Inc., effective July 8, 2026 (SPL set c44365e9-d470-4e35-978d-8565a9e3471e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Adalimumab-aaty | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Psoriasis, Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | $495.75 per unit 40 mg/0.4 mL autoinjector |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once